Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 (Lisaftoclax) + Azacitidine in R/R AML, MPAL, CMML, and MDS
NCT04964518Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose. Started Jul 2021; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04964518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964518.